Tag: Axovant Sciences
March 14, 2019
Axovant Sciences Announces Pricing of $40 Million Public Offering of Common Shares
Axovant Sciences (NASDAQ:AXGT) has announced the pricing of its underwritten public offering of 26.6 million of its common shares at... December 14, 2018
Axovant Sciences Announces Pricing of $30 Million Public Offering of Common Shares
Axovant Sciences (Nasdaq:AXON) announced the pricing of its underwritten public offering of 30,000,000 of its common shares at a price...
October 25, 2018
Axovant Doses First Patient in Parkinson’s Trial
The drug, AXO-Lenti-PD, was well tolerated and the patient was able to leave the hospital as expected with no side... October 25, 2018
Axovant Announces Dosing of First Patient in Clinical Study of AXO-Lenti-PD
Axovant Sciences (NASDAQ:AXON), a company developing innovative gene therapies for neurologic and neuromuscular diseases, announced dosing of the first patient... July 9, 2018
Axovant Announces Global Licensing Agreement for AXO-AAV-OPMD
Axovant Sciences (NASDAQ:AXON) today announced that it has licensed exclusive global rights to an investigational Silence-and-Replace gene therapy program from... June 6, 2018